Company profile for CanariaBio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

CanariaBio is a biotechnology company specializing in the development of new anticancer drugs and has research assets for the development of immunotherapy drugs. Through its subsidiaries, the company has a pipeline for the development of various immunotherapy drugs for ovarian cancer, pancreatic cancer, and metastatic breast cancer . The award started in earnest. FLORA-5 (oregobomab) received attention through world-class jou...
CanariaBio is a biotechnology company specializing in the development of new anticancer drugs and has research assets for the development of immunotherapy drugs. Through its subsidiaries, the company has a pipeline for the development of various immunotherapy drugs for ovarian cancer, pancreatic cancer, and metastatic breast cancer . The award started in earnest. FLORA-5 (oregobomab) received attention through world-class journals related to gynecological cancer because of its excellent results demonstrated in a phase 2 clinical trial.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
South Korea
Address
Address
23 Yongsugol-gil, Dongnam-gu, Cheonan-si, Chungcheongnam-do (Yonggok-dong)
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/canariabio-inc-announces-enrollment-completion-of-randomized-phase-2-study-of-oregovomab-in-combination-with-chemotherapy-as-neo-adjuvant-treatment-of-patients-with-advanced-ovarian-cancer-302228497.html

PR NEWSWIRE
23 Aug 2024

https://www.prnewswire.com/news-releases/canariabio-and-hikma-announce-the-signing-of-distribution-and-license-agreement-for-oregovomab-in-mena-region-301951620.html

PR NEWSWIRE
10 Oct 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty